The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and toxicity of pembrolizumab in addition to neoadjuvant platinum-based chemotherapy (NAPC) in triple-negative breast cancer (TNBC) patients with and without germline BRCA mutations (gBRCAmut).
 
Tal Etan
No Relationships to Disclose
 
Lior Cohen
No Relationships to Disclose
 
Amir Sonnenblick
Consulting or Advisory Role - AstraZeneca/Merck; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Progenetics; Rhenium/Oncotest; Roche; Stemline Therapeutics
Speakers' Bureau - Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Research Funding - Gilead Sciences; Novartis; Roche
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Medison; MSD; NeoPharm; Pfizer; Roche
 
Yael Bar
Honoraria - Gilaed; Lilly; MSD; Novartis; Oncotest/Rhenium; Pfizer; Roche; Stemline Therapeutics
Consulting or Advisory Role - Lilly; Novartis
 
Shir Lerner
No Relationships to Disclose
 
Irina Stefanski
No Relationships to Disclose
 
Iris Shiran
Honoraria - Novartis
Consulting or Advisory Role - Novartis
 
Shlomit Shachar
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Gilead Sciences; Pfizer; Roche